LANTERN PHARMA INC (LTRN) Stock News

USA - NASDAQ:LTRN - US51654W1018 - Common Stock

4.1 USD

+0.29 (+7.61%)

Last: 9/16/2025, 8:00:00 PM

4.02 USD

-0.08 (-1.95%)

After Hours: 9/16/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LTRN Latest News, Press Relases and Analysis

All

Press Releases

19 hours ago - By: Lantern Pharma Inc.

Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

14 days ago - By: Lantern Pharma Inc.

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

a month ago - By: ACCESS Newswire

RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26

a month ago - By: Benzinga - Mentions: TRIB UNH ONMD PAHC ...

12 Health Care Stocks Moving In Thursday's After-Market Session

4 months ago - By: Benzinga

Lantern Pharma's Earnings Outlook

a month ago - By: The Motley Fool

Lantern Pharma Narrows Loss in Q2

a month ago - By: Lantern Pharma Inc.

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

a month ago - By: Lantern Pharma Inc.

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

a month ago - By: Lantern Pharma Inc.

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

2 months ago - By: Lantern Pharma Inc.

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

2 months ago - By: Lantern Pharma Inc.

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

2 months ago - By: ACCESS Newswire

Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

2 months ago - By: Lantern Pharma Inc.

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

2 months ago - By: Lantern Pharma Inc.

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

2 months ago - By: Lantern Pharma Inc.

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

3 months ago - By: Lantern Pharma Inc.

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

4 months ago - By: Yahoo Finance - Mentions: REVB ESLT CTKB KROS ...

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

4 months ago - By: Yahoo Finance - Mentions: VREX CTKB KROS CADL ...

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

4 months ago - By: Lantern Pharma Inc.

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

6 months ago - By: Lantern Pharma Inc.

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

6 months ago - By: Lantern Pharma Inc.

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

7 months ago - By: Lantern Pharma Inc.

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

8 months ago - By: Lantern Pharma Inc.

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

9 months ago - By: Lantern Pharma Inc.

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

10 months ago - By: Lantern Pharma Inc.

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)